Y. Yen

Y. Yen, L. Leong, P. Frankel, 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Human ribonucleotide reductase M2 subunit gene amplification and transcriptional regulation in a homogeneous staining chromosome region responsible for the mechanism of drug resistance

Y. Yen, W. Qiu, X. Liu, 2002, Cytogenetic and Genome Research.

Electrochemical treatment of human KB cells in vitro.

C. Chou, Y. Yen, J. Yu, 1999, Bioelectromagnetics.

The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells.

P. Atadja, R. Jove, Y. Yen, 2007, Blood.

Using T‐cell repertoire profiles as predictor in a primary mucosal melanoma

Y. Yen, Wei-Chiao Chang, G. Lan, 2020, Clinical and translational medicine.

Preclinical effects of CRLX101, an investigational camptothecin-containing nanoparticle drug conjugate, on treating glioblastoma multiforme via apoptosis and antiangiogenesis

Y. Yen, Chien-Ju Lin, Ruei-Ming Chen, 2016, Oncotarget.

Bcl2 induces DNA replication stress by inhibiting ribonucleotide reductase.

W. Curran, F. Khuri, Y. Yen, 2014, Cancer research.

Structurally dependent redox property of ribonucleotide reductase subunit p53R2.

Lijun Xue, Y. Yen, Xiyong Liu, 2006, Cancer research.

Symptom concerns and quality of life in hepatobiliary cancers.

Y. Yen, B. Ferrell, L. Wagman, 2008, Oncology nursing forum.

Correction: HP1β Is a Biomarker for Breast Cancer Prognosis and PARP Inhibitor Therapy

Y. Yen, F. Qiu, Xiyong Liu, 2015, PloS one.

Role of the M2 subunit of ribonucleotide reductase in regulation by hydroxyurea of the activity of the anti-HIV-1 agent 2',3'-dideoxyinosine.

Y. Yen, B. Zhou, H. Mitsuya, 1998, Biochemical pharmacology.

Ribonucleotide Reductase Subunit One as Gene Therapy Target Ribonucleotide Reductase R1 Gene Therapy of Human Colon

Y. Yen, 2003 .

The ribonucleotide reductase subunit M2B subcellular localization and functional importance for DNA replication in physiological growth of KB cells.

Lijun Xue, Y. Yen, Xiyong Liu, 2005, Biochemical pharmacology.

Reciprocal regulation of autophagy and dNTP pools in human cancer cells

Y. Yen, Yun-Ru Chen, Lixin Yang, 2014, Autophagy.

Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A California Consortium (CCC-P) Trial.

Y. Yen, D. Gandara, H. Lenz, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mechanistic Control of Carcinoembryonic Antigen-related Cell Adhesion Molecule-1 (CEACAM1) Splice Isoforms by the Heterogeneous Nuclear Ribonuclear Proteins hnRNP L, hnRNP A1, and hnRNP M*

Y. Yen, S. Gaur, K. Dery, 2011, The Journal of Biological Chemistry.

Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors

Y. Yen, J. Doroshow, L. Leong, 1996, Cancer Chemotherapy and Pharmacology.

The role of peroxiredoxin II in radiation-resistant MCF-7 breast cancer cells.

Y. Yen, Jian Jian Li, J. Shively, 2005, Cancer research.

Ribonucleotide reductase small subunit M2B prognoses better survival in colorectal cancer.

Lijun Xue, Y. Yen, Xiyong Liu, 2011, Cancer research.

Chromosomal instability triggered by Rrm2b loss leads to IL-6 secretion and plasmacytic neoplasms.

Y. Yen, Lufen Chang, R. Guo, 2013, Cell reports.

Phase I Trial of Intraperitoneal Gemcitabine in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity

Y. Yen, J. Doroshow, L. Leong, 2007, Clinical Cancer Research.

A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer

M. Fishman, Y. Yen, J. Doroshow, 2004, Cancer Chemotherapy and Pharmacology.

Pilot trial of CRLX101 in patients with advanced, chemotherapy-refractory gastroesophageal cancer.

Mark E. Davis, Y. Yen, M. Fakih, 2017, Journal of Gastrointestinal Oncology.

A phase I trial of cixutumumab (C) (IMC-A12) and sorafenib (S) for treatment of advanced hepatocellular carcinoma (HCC).

Y. Yen, D. Gandara, H. Lenz, 2014 .

Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics.

Y. Yen, J. Doroshow, L. Leong, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Primary Cutaneous Anaplastic Large Cell Lymphoma With Positive ALK Expression and a Rapidly Progressive Cutaneous Nodule

Lijun Xue, Y. Yen, Xiuzhen Li, 2015, International journal of surgical pathology.

A predictive signature for oxaliplatin and 5-fluorouracil based chemotherapy in locally advanced gastric cancer

Y. Yen, Beisi Xu, Xiyong Liu, 2020, Translational oncology.

A study of radiotherapy modalities combined with continuous 5-FU infusion for locally advanced gastrointestinal malignancies.

Y. Yen, J. Doroshow, L. Leong, 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

The Novel Reductase Inhibitor COH29 Inhibits DNA Repair In Vitro.

Yate-Ching Yuan, Y. Yen, Xiyong Liu, 2015 .

Tumor suppressor FOXO3 regulates ribonucleotide reductase subunit RRM2B and impacts on survival of cancer patients

Y. Yen, Lixin Yang, Xiyong Liu, 2014, Oncotarget.

Novel regulators and molecular mechanisms of p53R2 and its disease relevance.

Y. Yen, E. Cho, 2016, Biochimie.

Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis.

Y. Yen, J. Doroshow, L. Leong, 1998, Cancer research.

Structural Basis on the Dityrosyl-Diiron Radical Cluster and the Functional Differences of Human Ribonucleotide Reductase Small Subunits hp53R2 and hRRM2

Yate-Ching Yuan, Y. Yen, Bingsen Zhou, 2010, Molecular Cancer Therapeutics.

A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study

Y. Yen, P. Frankel, Kenneth K. Chan, 2016, Leukemia & lymphoma.

Non-enzymatic action of RRM1 protein upregulates PTEN leading to inhibition of colorectal cancer metastasis

Z. Ling, Y. Yen, Xiyong Liu, 2015, Tumor Biology.

High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome

Y. Yen, J. Doroshow, L. Leong, 2001, British Journal of Cancer.

A simple and sensitive ribonucleotide reductase assay.

Y. Yen, A. Jong, C. Reynolds, 1998, Journal of biomedical science.

A Novel Multi-Target Small Molecule, LCC-09, Inhibits Stemness and Therapy-Resistant Phenotypes of Glioblastoma Cells by Increasing miR-34a and Deregulating the DRD4/Akt/mTOR Signaling Axis

D. Mukhopadhyay, Y. Yen, M. Hsiao, 2019, Cancers.

Characterization of enzymatic properties of human ribonucleotide reductase holoenzyme reconstituted in vitro from hRRM1, hRRM2, and p53R2 subunits.

Y. Yen, Bingsen Zhou, W. Qiu, 2006, Biochemical and biophysical research communications.

Jejunal Cancer with WRN Mutation Identified from Next-Generation Sequencing: A Case Study and Minireview

Y. Yen, Christopher Chang, H. Huang, 2014, Case reports in surgery.

leukemia cells DNA damage response genes and apoptosis in Ph- acute lymphoblastic The novel histone deacetylase inhibitor, LBH589, induces expression of

P. Atadja, R. Jove, Y. Yen, 2013 .

Integrin β3 and LKB1 are independently involved in the inhibition of proliferation by lovastatin in human intrahepatic cholangiocarcinoma

Y. Yen, Yun-Ru Liu, Hung-Yun Lin, 2015, Oncotarget.

A novel histone deacetylase inhibitor MPT0L184 dysregulates cell-cycle checkpoints and initiates unscheduled mitotic signaling.

Y. Yen, S. Pan, Sung-Bau Lee, 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Inhibitory mechanisms of heterocyclic carboxaldehyde thiosemicabazones for two forms of human ribonucleotide reductase.

Y. Yen, Bingsen Zhou, Lijun Zhu, 2009, Biochemical pharmacology.

Metastasis-Suppressing Potential of Ribonucleotide Reductase Small Subunit p53R2 in Human Cancer Cells

Lijun Xue, Y. Yen, Xiyong Liu, 2006, Clinical Cancer Research.

Study the property of double-ended fluoroalkyl poly(ethylene glycol) hydrogel as a depot for hydrophobic drug delivery using electron paramagnetic resonance technique and cell proliferation assay

Lijun Xue, Y. Yen, Bingsen Zhou, 2008 .

Rrm2b deletion causes mitochondrial metabolic defects in renal tubules

Y. Yen, Mai-Szu Wu, I. Lin, 2019, Scientific Reports.

Ribonucleotide reductase subunit p53R2 regulates mitochondria homeostasis and function in KB and PC-3 cancer cells.

Lijun Xue, Y. Yen, Xiyong Liu, 2011, Biochemical and biophysical research communications.

Molecular Cancer Therapeutics Structural Basis on the Dityrosyl-Diiron Radical Cluster and the Functional Differences of Human Ribonucleotide Reductase Small Subunits hp 53 R 2 and hRRM 2

Yate-Ching Yuan, Y. Yen, Bingsen Zhou, 2010 .

Redox property of ribonucleotide reductase small subunit M2 and p53R2.

Lijun Xue, Y. Yen, Xiyong Liu, 2008, Methods in molecular biology.

Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer.

Lijun Xue, Y. Yen, Xiyong Liu, 2007, Clinical colorectal cancer.

Production of a monoclonal antibody against the hRRM2 subunit of ribonucleotide reductase and immunohistochemistry study of human cancer tissues.

Y. Yen, Xiyong Liu, P. Chu, 2006, Hybridoma.

A Ferrous-triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase

Y. Yen, Bingsen Zhou, Lijun Zhu, 2006, Molecular Cancer Therapeutics.

Enzymatic property analysis of p53R2 subunit of human ribonucleotide reductase.

Y. Yen, Bingsen Zhou, J. Shih, 2006, Advances in enzyme regulation.

A dityrosyl-diiron radical cofactor center is essential for human ribonucleotide reductases

Yate-Ching Yuan, Y. Yen, Bingsen Zhou, 2005, Molecular Cancer Therapeutics.

Determination of the potency and subunit-selectivity of ribonucleotide reductase inhibitors with a recombinant-holoenzyme-based in vitro assay.

Yate-Ching Yuan, Y. Yen, Bingsen Zhou, 2005, Biochemical pharmacology.

Nuclear factor Y regulation and promoter transactivation of human ribonucleotide reductase subunit M2 gene in a Gemcitabine resistant KB clone.

Lijun Xue, Y. Yen, Xiyong Liu, 2004, Biochemical pharmacology.

Advances in Brief In Vitro Characterization of Enzymatic Properties and Inhibition of the p 53 R 2 Subunit of Human Ribonucleotide Reductase

Yate-Ching Yuan, Y. Yen, Bingsen Zhou, 2004 .

First-in-human phase I trial of a cyclodextrin-containing polymer-camptothecin nanoparticle in patients with solid tumors

Mark E. Davis, Y. Yen, T. Schluep, 2007 .

Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial

Y. Yen, J. Doroshow, D. Gandara, 2002, Cancer Chemotherapy and Pharmacology.

γ-H2AX Kinetics as a Novel Approach to High Content Screening for Small Molecule Radiosensitizers

Y. Yen, Ming-Ming Zhou, J. Kao, 2012, PloS one.

Intrahepatic cholangiocarcinoma and hepatitis: case study and literature review.

Y. Yen, P. Chu, F. Luh, 2009, Anticancer research.

Systemic delivery of siRNA via targeted nanoparticles in patients with cancer: Results from a first-in-class phase I clinical trial.

Mark E. Davis, D. Seligson, J. Zuckerman, 2010 .

Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer.

Y. Yen, J. Doroshow, L. Leong, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Bortezomib therapeutic effect is associated with expression of FGFR3 in multiple myeloma cells.

Y. Yen, Bingsen Zhou, G. Somlo, 2009, Anticancer research.

Identification of a new class of WNT1 inhibitor: Cancer cells migration, G-quadruplex stabilization and target validation

Y. Yen, Shih-Hsiung Wu, Hsu-Shan Huang, 2015, Oncotarget.

Synthesis and ribonucleotide reductase inhibitory activity of thiosemicarbazones.

Y. Yen, Bingsen Zhou, Arijit Basu, 2008, Bioorganic & medicinal chemistry letters.

Ribonucleotide reductase inhibitors and future drug design.

Y. Yen, Bingsen Zhou, J. Shao, 2006, Current cancer drug targets.

Targeting ribonucleotide reductase for cancer therapy

Y. Yen, Xiyong Liu, Lijun Zhu, 2013, Expert opinion on therapeutic targets.

Human Mitotic Centromere-Associated Kinesin Is Targeted by MicroRNA 485-5p/181c and Prognosticates Poor Survivability of Breast Cancer

Lijun Xue, Y. Yen, Xiyong Liu, 2019, Journal of oncology.

Time and sequence dependence of hydroxyurea in combination with gemcitabine in human KB cells.

Y. Yen, Bingsen Zhou, S. Mi, 2002, Anticancer research.

Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer.

Yun Yen, Mark E. Davis, Y. Yen, 2012, Nanomedicine : nanotechnology, biology, and medicine.

Berbamine Inhibits the Growth of Liver Cancer Cells and Cancer-Initiating Cells by Targeting Ca2+/Calmodulin-Dependent Protein Kinase II

Y. Yen, Z. Meng, Wendong Huang, 2013, Molecular Cancer Therapeutics.

Berbamine Inhibits the Growth of Liver Cancer Cells and Cancer-Initiating Cells by Targeting Ca 2þ /Calmodulin-

Y. Yen, Z. Meng, Wendong Huang, 2013 .

Case report: herpes simplex encephalitis in cancer patients.

Y. Yen, P. Chu, C. Yen, 2009, Bioscience trends.

Reversal of hydroquinone-mediated suppression of T cell proliferation by transfection of the M2 subunit of ribonucleotide reductase.

Y. Yen, Q. Li, B. Freed, 1998, Toxicology and applied pharmacology.

Arginine starvation-associated atypical cellular death involves mitochondrial dysfunction, nuclear DNA leakage, and chromatin autophagy

Frank Y. S. Chuang, L. Xing, Y. Yen, 2014, Proceedings of the National Academy of Sciences.

Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-ĸB signaling, and synergizes with an ERK inhibitor.

R. Jove, Y. Yen, A. Scuto, 2012, Cancer biology & therapy.

Human mitochondrial pyrroline-5-carboxylate reductase 1 promotes invasiveness and impacts survival in breast cancers

Lijun Xue, Y. Yen, Xiyong Liu, 2017, Carcinogenesis.

Antitumor Activity of Targeting Src Kinases in Endothelial and Myeloid Cell Compartments of the Tumor Microenvironment

Hua Yu, R. Jove, Y. Yen, 2010, Clinical Cancer Research.

Wnt modulates MCL1 to control cell survival in triple negative breast cancer

J. Li, Y. Yen, Yun-Ru Chen, 2014, BMC Cancer.

Autophagy induction causes a synthetic lethal sensitization to ribonucleotide reductase inhibition in breast cancer cells

Y. Yen, Yun-Ru Chen, Xiyong Liu, 2015, Oncotarget.

Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor.

Yun Yen, Fan Yang, David D Moore, 2007, Cancer research.

Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential

Yun Yen, Y. Yen, Bing-Sen Zhou, 1998, Clinical & Experimental Metastasis.

Phase I study of cisdiamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies

J. Niland, Y. Yen, J. Doroshow, 2003, Cancer Chemotherapy and Pharmacology.

The Feasibility of Total or Near-Total Bilateral Thyroidectomy for the Treatment of Bilateral Multinodular Goiter

Y. Yen, P. Chu, W. Qiu, 2009, Journal of investigative surgery : the official journal of the Academy of Surgical Research.

A Simple and Sensitive Ribonucleotide Reductase Assay

Y. Yen, Kefei Yu, A. Jong, 1998, Journal of Biomedical Science.

Synthesis and biological activity of novel N6-substituted and 2,N6-disubstituted adenine ribo- and 3'-C-methyl-ribonucleosides as antitumor agents.

Y. Yen, Bingsen Zhou, R. Petrelli, 2011, European journal of medicinal chemistry.

Overexpression of Uridine-Cytidine Kinase 2 Correlates with Breast Cancer Progression and Poor Prognosis

Y. Yen, Xiyong Liu, Guohui Ding, 2017, Journal of breast cancer.

Ribonucleotide Reductase Large Subunit M1 Predicts Poor Survival Due to Modulation of Proliferative and Invasive Ability of Gastric Cancer

Yun Yen, Shengjie Zhang, Jianguo Shen, 2013, PloS one.

An overview of the rare parotid gland cancer

Y. Yen, D. Ann, P. Chu, 2011, Head & neck oncology.

Differences in silencing of mismatched targets by sliced versus diced siRNAs

A. Riggs, Guihua Sun, Y. Yen, 2018, Nucleic acids research.

Ribonucleotide reductase subunit M2B deficiency leads to mitochondrial permeability transition pore opening and is associated with aggressive clinicopathologic manifestations of breast cancer.

Lijun Xue, Y. Yen, Xiyong Liu, 2018, American journal of translational research.

A subpopulation of CD133(+) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy.

Y. Yen, A. Le, Jimmy J. Brown, 2010, Cancer letters.

Inhibition of protein phosphorylation in MIA pancreatic cancer cells: confluence of metabolic and signaling pathways.

Y. Yen, R. Recker, V. Go, 2010, Journal of proteome research.

The EGF/hnRNP Q1 axis is involved in tumorigenesis via the regulation of cell cycle-related genes

Y. Yen, Chang-Shen Lin, Liang-Yi Hung, 2018, Experimental & Molecular Medicine.

High-Mobility Group A2 Protein Modulates hTERT Transcription To Promote Tumorigenesis

Y. Yen, H. Shih, D. Ann, 2011, Molecular and Cellular Biology.

Overexpression of HMGA2 Promotes Metastasis and Impacts Survival of Colorectal Cancers

Lijun Xue, Y. Yen, Xiyong Liu, 2011, Clinical Cancer Research.

Predictive Biomarkers and Personalized Medicine Overexpression of HMGA 2 Promotes Metastasis and Impacts Survival of Colorectal Cancers

Lijun Xue, Y. Yen, Xiyong Liu, 2011 .

Suppression of nonhomologous end joining repair by overexpression of HMGA2.

David J. Chen, Benjamin P. C. Chen, Y. Yen, 2009, Cancer research.

High mobility group A2 potentiates genotoxic stress in part through the modulation of basal and DNA damage-dependent phosphatidylinositol 3-kinase-related protein kinase activation.

Y. Yen, D. Ann, M. O’Reilly, 2005, Cancer research.

Long noncoding RNA LncHIFCAR/MIR31HG is a HIF-1α co-activator driving oral cancer progression

Y. Yen, H. Kung, Cheng-Ying Chu, 2017, Nature Communications.

Transcriptional regulation by targeted expression of architectural transcription factor high mobility group A2 in salivary glands of transgenic mice.

Y. Yen, D. Ann, Y. Ho, 2007, European journal of oral sciences.

miR-26a enhances miRNA biogenesis by targeting Lin28B and Zcchc11 to suppress tumor growth and metastasis

R. Jove, Y. Yen, Z. Meng, 2014, Oncogene.

Expression of DNA Translesion Synthesis Polymerase η in Head and Neck Squamous Cell Cancer Predicts Resistance to Gemcitabine and Cisplatin-Based Chemotherapy

Y. Yen, Xiyong Liu, P. Chu, 2013, PloS one.

miR-103/107 prolong Wnt/β-catenin signaling and colorectal cancer stemness by targeting Axin2

Y. Yen, Yun-Ru Liu, Hsin-Yi Chen, 2019, Scientific Reports.

Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis.

Weiying Zhou, Yun Yen, Yang Yu, 2014, Cancer cell.

Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status

Y. Yen, S. Gaur, Yafan Wang, 2014, Molecular Cancer.

Clinicopathologic significance of synchronous and metachronous adenomas in colorectal cancer.

Y. Yen, P. Frankel, D. David, 2005, Clinical colorectal cancer.

Arginine Signaling and Cancer Metabolism

Y. Yen, H. Kung, S. Hsu, 2021, Cancers.

Arginine is an epigenetic regulator targeting TEAD4 to modulate OXPHOS in prostate cancer cells

Y. Yen, H. Kung, Cheng-Ying Chu, 2021, Nature Communications.

Targeting Autophagy by MPT0L145, a Highly Potent PIK3C3 Inhibitor, Provides Synergistic Interaction to Targeted or Chemotherapeutic Agents in Cancer Cells

Y. Yen, Tsung-Han Hsieh, Yun-Ru Liu, 2019, Cancers.

Amplification of FRS2 and activation of FGFR/FRS2 signaling pathway in high-grade liposarcoma.

Kevin C. Chu, Hanlin Gao, Jinhui Wang, 2013, Cancer research.

Molecular and Cellular Pathobiology Ampli fi cation of FRS 2 andActivation of FGFR / FRS 2 Signaling Pathway in High-Grade Liposarcoma

So, Hanlin Gao, Jinhui Wang, 2013 .

The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival

R. Jove, Y. Yen, A. Scuto, 2011, Leukemia.

UC Office of the President Recent Work Title De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer

Weiying Zhou, Yun Yen, John J Rossi, 2012 .

Human papillomavirus and non‐small cell lung cancer

Y. Yen, Ya‐Wen Cheng, Hue Lee, 2013, Thoracic cancer.

Mutants TP53 p.R273H and p.R273C but not p.R273G Enhance Cancer Cell Malignancy

Yate-Ching Yuan, J. Li, Y. Yen, 2014, Human mutation.

Determination of deoxyribonucleoside triphosphate pool sizes in ribonucleotide reductase cDNA transfected human KB cells.

Y. Yen, J. Yu, B. Zhou, 1998, Biochemical pharmacology.

HP1β Is a Biomarker for Breast Cancer Prognosis and PARP Inhibitor Therapy

Y. Yen, F. Qiu, Xiyong Liu, 2015, PloS one.

The Ambivalent Role of lncRNA Xist in Carcinogenesis

Y. Yen, Yung-Kang Chen, 2019, Stem Cell Reviews and Reports.

A Distinct Metabolic Signature of Human Colorectal Cancer with Prognostic Potential

D. Xie, Y. Yen, L. Xu, 2014, Clinical Cancer Research.

Novel Common Genetic Susceptibility Loci for Colorectal Cancer

Stephanie A. Bien, Elizabeth L. Barry, Aung Ko Win, 2018, Journal of the National Cancer Institute.

Molecular Properties, Functional Mechanisms, and Applications of Sliced siRNA

Guihua Sun, Y. Yen, B. Yung, 2015, Molecular therapy. Nucleic acids.

Ribozyme cleavage leads to decreased expression of fibroblast growth factor receptor 3 in human multiple myeloma cells, which is associated with apoptosis and downregulation of vascular endothelial growth factor.

Y. Yen, P. Chu, J. Rossi, 2005, Oligonucleotides.

Markers for efficacy of mammalian target of rapamycin inhibitor.

Y. Yen, Y. Liao, Alex Sy, 2012, Anticancer research.

Down-regulation of growth arrest DNA damage-inducible gene 45beta expression is associated with human hepatocellular carcinoma.

Y. Yen, Xiyong Liu, P. Chu, 2003, The American journal of pathology.

The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers.

Yun Yen, Y. Yen, Xiyong Liu, 2014, Urologic oncology.

A sequential treatment of depsipeptide followed by 5-azacytidine enhances Gadd45beta expression in hepatocellular carcinoma cells.

Lijun Xue, Y. Yen, Xiyong Liu, 2007, Anticancer research.

Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma

Y. Yen, M. Slovak, Xiyong Liu, 2005, Molecular Cancer Therapeutics.

Inhibitors of mTOR overcome drug resistance from topoisomerase II inhibitors in solid tumors.

Y. Yen, Lixin Yang, S. Gaur, 2011, Cancer letters.

Bisphosphonates suppress insulin‐like growth factor 1‐induced angiogenesis via the HIF‐1α/VEGF signaling pathways in human breast cancer cells

Y. Yen, Keyuan Zhou, A. Le, 2010, International journal of cancer.

Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study

Y. Yen, J. Doroshow, D. Gandara, 2009, Cancer Chemotherapy and Pharmacology.

Characterization of the human ribonucleotide reductase M2 subunit gene; genomic structure and promoter analyses

Y. Yen, B. Zhou, Y. Yen, 2001, Cytogenetic and Genome Research.

Inhibition of human cancer cell growth by inducible expression of human ribonucleotide reductase antisense cDNA.

Y. Yen, B. Zhou, F. He, 2000, Antisense & nucleic acid drug development.

Characterization of a hydroxyurea-resistant human KB cell line with supersensitivity to 6-thioguanine.

Y. Yen, Y. Cheng, B. Zhou, 1994, Cancer research.

Mammalian target of rapamycin and head and neck squamous cell carcinoma

Y. Yen, Y. Liao, Charles Kim, 2011, Head & neck oncology.

NCCN Task Force Report: mTOR inhibition in solid tumors.

P. Febbo, D. Ettinger, R. Figlin, 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

Ovarian Cancer: Opportunity for Targeted Therapy

Y. Yen, J. Mortimer, R. Morgan, 2011, Journal of oncology.

Role for KAP1 Serine 824 Phosphorylation and Sumoylation/Desumoylation Switch in Regulating KAP1-mediated Transcriptional Repression*

Y. Yen, H. Shih, D. Ann, 2007, Journal of Biological Chemistry.

ROS1 as a ‘druggable’ receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway

S. Ou, Y. Yen, R. Soo, 2012, Expert review of anticancer therapy.

Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma.

D. Mukhopadhyay, Y. Yen, Krishnendu Pal, 2019, Bioconjugate chemistry.

LKB1 deficiency promotes proliferation and invasion of glioblastoma through activation of mTOR and focal adhesion kinase signaling pathways.

Y. Yen, Xiyong Liu, P. Chu, 2019, American journal of cancer research.

Underexpression of LKB1 tumor suppressor is associated with enhanced Wnt signaling and malignant characteristics of human intrahepatic cholangiocarcinoma

Chao Guo, Bing Mu, Jinhui Wang, 2015, Oncotarget.

A bias-reducing strategy in profiling small RNAs using Solexa.

Guihua Sun, Hanlin Gao, Jinhui Wang, 2011, RNA.

Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels.

R. Jove, Y. Yen, A. Scuto, 2011, Cancer research.

Potent siRNA Inhibitors of Ribonucleotide Reductase Subunit RRM2 Reduce Cell Proliferation In vitro and In vivo

Mark E. Davis, Y. Yen, J. Heidel, 2007, Clinical Cancer Research.

RRM2B Suppresses Activation of the Oxidative Stress Pathway and is Up-regulated by P53 During Senescence

Lijun Xue, Y. Yen, P. Chu, 2012, Scientific Reports.

The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor

Y. Yen, Lixin Yang, S. Gaur, 2015, Oncotarget.

FZD 7 in Triple Negative Breast Cancer Cells

Y. Yen, Lixin Yang, Charles Kim, 2012 .

FZD7 in Triple Negative Breast Cancer Cells

Y. Yen, Lixin Yang, Charles Kim, 2011 .

Amyand's Hernia in Elderly Patients: Diagnostic, Anesthetic, and Perioperative Considerations

Y. Yen, P. Chu, W. Qiu, 2009, Journal of investigative surgery : the official journal of the Academy of Surgical Research.

Hepatocarcinogenesis in FXR-/- mice mimics human HCC progression that operates through HNF1α regulation of FXR expression.

Y. Yen, Xiyong Liu, B. M. Forman, 2012, Molecular endocrinology.

Altered splicing of CEACAM1 in breast cancer: Identification of regulatory sequences that control splicing of CEACAM1 into long or short cytoplasmic domain isoforms

Y. Yen, S. Gaur, J. Shively, 2008, Molecular Cancer.

Ethnic differences in the behavior of hepatocellular carcinoma

Y. Yen, T. Odom-Maryon, L. Wagman, 1999, Cancer.

Autoantibodies as potential biomarkers for breast cancer

Y. Yen, K. Kernstine, L. Zhong, 2008, Breast Cancer Research.

Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle

Mark E. Davis, J. Zuckerman, Y. Yen, 2013, Proceedings of the National Academy of Sciences.

First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies

Yun Yen, Glen J. Weiss, Mark E. Davis, 2013, Investigational New Drugs.

Canonical nuclear factor κB pathway links tumorigenesis of synchronous mantle-cell lymphoma, clear-cell renal-cell carcinoma, and GI stromal tumor.

Yate-Ching Yuan, Y. Yen, D. Ann, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA

Mark E. Davis, J. Zuckerman, A. Tolcher, 2014, Proceedings of the National Academy of Sciences.

Annexin‐I as a potential target for green tea extract induced actin remodeling

J. Rao, R. Figlin, A. Belldegrun, 2007, International journal of cancer.

MicroRNA‐657 promotes tumorigenesis in hepatocellular carcinoma by targeting transducin‐like enhancer protein 1 through nuclear factor kappa B pathways

Y. Yen, Lixin Yang, Xiyong Liu, 2013, Hepatology.

Upregulation of Protein Synthesis and Proteasome Degradation Confers Sensitivity to Proteasome Inhibitor Bortezomib in Myc-Atypical Teratoid/Rhabdoid Tumors

Y. Yen, K. Hsieh, Shih-Chieh Lin, 2020, Cancers.

Expression of glypican 3 enriches hepatocellular carcinoma development-related genes and associates with carcinogenesis in cirrhotic livers.

Lijun Xue, Y. Yen, Xiyong Liu, 2015, Carcinogenesis.

The Novel Ribonucleotide Reductase Inhibitor COH29 Inhibits DNA Repair In Vitro

Yate-Ching Yuan, Y. Yen, Xiyong Liu, 2015, Molecular Pharmacology.

A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance.

Yun Yen, David Horne, Yate-Ching Yuan, 2013, Cancer research.

CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing

Yun Yen, Mark E. Davis, James Lin, 2016, Proceedings of the National Academy of Sciences.

Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer.

Yun Yen, Mark E. Davis, Yate-Ching Yuan, 2014, Nanomedicine : nanotechnology, biology, and medicine.

A germline missense mutation in COQ6 is associated with susceptibility to familial schwannomatosis

H. Chiou, Hanlin Gao, Jinhui Wang, 2014, Genetics in Medicine.

Host immune response to anti-cancer camptothecin conjugated cyclodextrin-based polymers

Mark E. Davis, Y. Yen, C. Changou, 2019, Journal of Biomedical Science.

Long-term Proton Pump Inhibitor Administration Caused Physiological and Microbiota Changes in Rats

Y. Yen, P. Chu, Wei Jia, 2020, Scientific Reports.

The Plication and Splinting Procedure for Idiopathic Sclerosing Encapsulating Peritonitis

Y. Yen, P. Chu, W. Qiu, 2009, Journal of investigative surgery : the official journal of the Academy of Surgical Research.

Therapeutic effects of thalidomide in myeloma are associated with the expression of fibroblast growth factor receptor 3

Y. Yen, Bingsen Zhou, G. Somlo, 2005, Therapeutics and clinical risk management.

Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer

Y. Yen, J. Doroshow, D. Gandara, 2004, Cancer Chemotherapy and Pharmacology.

Trichlorobenzene-substituted azaaryl compounds as novel FGFR inhibitors exhibiting potent antitumor activity in bladder cancer cells in vitro and in vivo

Y. Yen, Yun-Ru Liu, S. Pan, 2016, Oncotarget.

Colo-pancreaticoduodenectomy for locally advanced colon carcinoma—feasibility in patients presenting with acute abdomen

Y. Yen, Cheng‐Chung Wu, F. P'eng, 2021, World Journal of Emergency Surgery.

Colo-pancreaticoduodenectomy for Locally Advanced Colon Carcinoma- feasibility in patients manifesting as Acute Abdomen

Y. Yen, Cheng‐Chung Wu, F. P'eng, 2020 .

Benzodiazepines use and breast cancer risk: A population-based study and gene expression profiling evidence

Phung Anh Nguyen, Hsuan-Chia Yang, Yu-Chuan Li, 2017, J. Biomed. Informatics.

Precision Medicine and Pancreatic Cancer: A Gemcitabine Pathway Approach

Zhong Zheng, Yun Yen, Chandan Guha, 2016, Pancreas.

Dual Inhibition of PIK3C3 and FGFR as a New Therapeutic Approach to Treat Bladder Cancer

Y. Yen, Cheng-Ying Chu, Tsung-Han Hsieh, 2017, Clinical Cancer Research.

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO.

Y. Yen, G. Bhattacharyya, S. Choo, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II Study of Oxaliplatin in Patients With Unresectable, Metastatic, or Recurrent Hepatocellular Cancer: A California Cancer Consortium Trial

Y. Yen, D. Gandara, H. Lenz, 2008, American journal of clinical oncology.

Lowered circulating aspartate is a metabolic feature of human breast cancer

Yun Yen, Wei Jia, Yurii B. Shvetsov, 2015, Oncotarget.

Proton pump inhibitors and risk of periampullary cancers—A nested case–control study

H. Chiou, Y. Yen, Ming-Tsang Chuang, 2015, International journal of cancer.

Genome-wide CRISPR/Cas9 knockout screening uncovers a novel inflammatory pathway critical for resistance to arginine-deprivation therapy

Y. Yen, H. Kung, Cheng-Ying Chu, 2021, Theranostics.

DHS (Trans-4,4’-Dihydroxystilbene) Suppresses DNA Replication and Tumor Growth by Inhibiting RRM2 (Ribonucleotide Reductase Regulatory Subunit M2)

M. DePamphilis, Y. Yen, Wenge Zhu, 2018, Oncogene.

PYCR1 and PYCR2 Interact and Collaborate with RRM2B to Protect Cells from Overt Oxidative Stress

Michael J. Sweredoski, Y. Yen, Wei Jia, 2016, Scientific Reports.

Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers

Lijun Xue, Y. Yen, Xiyong Liu, 2012, Clinical science.

核糖核苷酸还原酶和非小细胞肺癌

Y. Yen, Ya‐Wen Cheng, Hue Lee, 2012, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study

Y. Yen, D. Gandara, S. Ramalingam, 2012, Cancer Chemotherapy and Pharmacology.

p53R2 Inhibits the Proliferation of Human Cancer Cells in Association with Cell-Cycle Arrest

Y. Yen, Xiyong Liu, D. Ann, 2011, Molecular Cancer Therapeutics.

1 p 53 R 2 inhibits the proliferation of human cancer cells in association with cell cycle arrest

Y. Yen, Xiyong Liu, D. Ann, 2011 .

Therapeutic Discovery p 53 R 2 Inhibits the Proliferation of Human Cancer Cells in Association with Cell-Cycle Arrest

Y. Yen, Xiyong Liu, D. Ann, 2011 .

2.6 A X-ray crystal structure of human p53R2, a p53-inducible ribonucleotide reductase .

Yate-Ching Yuan, Y. Yen, Bingsen Zhou, 2009, Biochemistry.

ATM-mediated serine 72 phosphorylation stabilizes ribonucleotide reductase small subunit p53R2 protein against MDM2 to DNA damage

Y. Yen, Xiyong Liu, Lufen Chang, 2008, Proceedings of the National Academy of Sciences.

Ribonucleotide reductase subunit one as gene therapy target: commentary re: M-Y. Cao et al., Adenovirus-mediated ribonucleotide reductase R1 gene therapy of human colon adenocarcinoma. Clin. Cancer Res., 9: 4304-4308, 2003.

Y. Yen, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits.

Lijun Xue, Y. Yen, Xiyong Liu, 2003, Cancer research.

Adenovirus-mediated Ribonucleotide Reductase R 1 Gene Therapy of Human Colon Adenocarcinoma

Y. Yen, 2003 .

p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8+ T-cell Responses

Y. Yen, M. Fakih, L. Leong, 2014, Clinical Cancer Research.

8 Growth arrest DMA damage-inducible gene 45 β in human hepatocellular carcinoma

Y. Yen, 2005 .

Randomized trial of oral cyclophosphamide versus oral cyclophosphamide with celecoxib for recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Y. Yen, L. Leong, P. Frankel, 2019, Cancer treatment and research communications.

Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication.

Qianjun Li, H. Wakimoto, R. Martuza, 2010, Cancer research.

Signature miRNAs in colorectal cancers were revealed using a bias reduction small RNA deep sequencing protocol

Yun Yen, Guihua Sun, Jinhui Wang, 2015, Oncotarget.

Arginine starvation kills tumor cells through aspartate exhaustion and mitochondrial dysfunction

Dustin E. Schones, Y. Yen, Yun-Ru Chen, 2018, Communications Biology.

Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies

Y. Yen, J. Doroshow, L. Leong, 2004, Cancer Chemotherapy and Pharmacology.

Efficient Radiomics-Based Classification of Multi-Parametric MR Images to Identify Volumetric Habitats and Signatures in Glioblastoma: A Machine Learning Approach

Y. Yen, Fang-Ying Chiu, 2022, Cancers.

A meta-analysis of randomized controlled trials

Y. Yen, Chiehfeng Chen, K. Tam, 2016 .

Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors

Yun Yen, James H. Doroshow, Adam Mamelak, 2010, Cancer Chemotherapy and Pharmacology.

Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy.

S. Vuk-Pavlović, Y. Yen, J. Doroshow, 1999, Blood.

Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer

Y. Yen, L. Leong, G. Somlo, 2001, Bone Marrow Transplantation.

CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.

Y. Yen, Sung-Bau Lee, J. Liou, 2021, European journal of medicinal chemistry.

Purine/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors.

Y. Yen, Sung-Bau Lee, J. Liou, 2020, European journal of medicinal chemistry.

Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: Comparison of real‐time reverse transcription‐PCR vs. Relative quantification reverse transcription‐PCR utilizing DNA sequencer analysis of PCR products

Y. Yen, J. Doroshow, D. Gandara, 2003, Journal of clinical laboratory analysis.

Cancers in Taiwan: Practical insight from epidemiology, treatments, biomarkers, and cost.

Y. Yen, H. Tsai, Wei-Chiao Chang, 2020, Journal of the Formosan Medical Association = Taiwan yi zhi.

Mass Spectrometry-Based Quantitative Metabolomics Revealed a Distinct Lipid Profile in Breast Cancer Patients

Y. Yen, Bingsen Zhou, W. Jia, 2013, International journal of molecular sciences.

Implications of salivary proteomics in drug discovery and development: a focus on cancer drug discovery.

Y. Yen, D. Ann, D. Wong, 2007, Drug discovery today.

Does long-term use of antidiabetic drugs changes cancer risk?

U. Iqbal, Y. Yen, Hsuan-Chia Yang, 2019, Medicine.

Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in estrogen-negative breast cancers

Lijun Xue, Y. Yen, Xiyong Liu, 2014, BMC Cancer.

Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway

Y. Yen, Wei-Chiao Chang, F. Luh, 2019, Journal of Biomedical Science.

A homozygous variant in RRM2B is associated with severe metabolic acidosis and early neonatal death.

R. Fulbright, Y. Yen, W. Ji, 2019, European journal of medical genetics.

Identification of F-box/LLR-repeated

Y. Yen, G. Xiao, H. Chew, 2009 .

A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A

Y. Yen, J. Doroshow, L. Leong, 2000, Cancer Chemotherapy and Pharmacology.

The Surgeon’s Role in Cancer Prevention. The Model in Colorectal Carcinoma

Y. Yen, D. David, D. Chu, 2007, Annals of Surgical Oncology.

Enhanced radiation response in radioresistant MCF-7 cells by targeting peroxiredoxin II

Y. Yen, Tieli Wang, Daniel Tamae, 2013, Breast cancer.

A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

Yun Yen, Hedy L. Kindler, Regina Gandour-Edwards, 2009, Cancer Chemotherapy and Pharmacology.

An increase of cytochrome C oxidase mediated disruption of gemcitabine incorporation into DNA in a resistant KB clone.

Lijun Xue, Y. Yen, Xiyong Liu, 2007, Biochemical pharmacology.

Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment.

Y. Yen, A. Vassilakos, H. Chew, 2006, Oncology reports.

Modulating ICBP90 to suppress human ribonucleotide reductase M2 induction restores sensitivity to hydroxyurea cytotoxicity.

Y. Yen, C. Bronner, Bingsen Zhou, 2006, Anticancer research.

Case report: Occurrence of fallopian tube cancer in a patient with previous history of estrogen receptor positive breast cancer.

Y. Yen, P. Chu, Michelle Lee, 2009, Bioscience trends.

A Newly Identified Variation at the Entry of the Recurrent Laryngeal Nerve into the Larynx

Y. Yen, Yang Wang, P. Chu, 2010, Journal of investigative surgery : the official journal of the Academy of Surgical Research.

Tyrosine kinase inhibitors for advanced or metastatic thyroid cancer: a meta-analysis of randomized controlled trials

E. Loh, Y. Yen, Chiehfeng Chen, 2018, Current medical research and opinion.

Hepatobiliary Cancers Clinical Practice Guidelines in OncologyTM

S. Curley, A. Benson, J. Marrero, 2009 .

Is Long-term Use of Benzodiazepine a Risk for Cancer?

Hsuan-Chia Yang, Min-Huei Hsu, Usman Iqbal, 2015, Medicine.

Secreted Protein Acidic and Rich in Cysteines-like 1 Suppresses Aggressiveness and Predicts Better Survival in Colorectal Cancers

Ying Yuan, Yun Yen, Weiting Ge, 2012, Clinical Cancer Research.

Systemic delivery of siRNA nanoparticles targeting RRM2 suppresses head and neck tumor growth.

Mark E. Davis, J. Zuckerman, C. H. J. Choi, 2012, Journal of controlled release : official journal of the Controlled Release Society.

Emerging role of autophagy during ischemia-hypoxia and reperfusion in hepatocellular carcinoma.

Y. Yen, D. Ann, W. Qiu, 2012, International journal of oncology.

Predicting malignancy: subsolid nodules detected on LDCT in a surgical cohort of East Asian patients

Y. Yen, C. Tzao, Yen-Kuang Lin, 2020, Journal of thoracic disease.

A dose escalation and pharmacodynamic study of triapine and radiation in patients with locally advanced pancreas cancer.

M. Grever, M. Knopp, Xin Wu, 2012, International journal of radiation oncology, biology, physics.

Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy.

Y. Yen, J. Doroshow, L. Leong, 2004, Journal of Clinical Oncology.

Chicken-Derived Humanized Antibody Targeting a Novel Epitope F2pep of Fibroblast Growth Factor Receptor 2: Potential Cancer Therapeutic Agent

Y. Yen, K. Tsai, Tsai-Yu Lin, 2019, ACS Omega.

Frequent Overexpression of HMGA2 in Human Atypical Teratoid/Rhabdoid Tumor and Its Correlation with let-7a3/let-7b miRNA

Guihua Sun, Hanlin Gao, Bing Mu, 2014, Clinical Cancer Research.

Frequent Overexpression of HMGA 2 in Human Atypical Teratoid / Rhabdoid Tumor and Its Correlation with let-7 a 3 / let-7 b miRNA

Guihua Sun, Hanlin Gao, Bing Mu, 2014 .

Serum and Urine Metabolite Profiling Reveals Potential Biomarkers of Human Hepatocellular Carcinoma*

Y. Yen, Ping Liu, L. Xu, 2011, Molecular & Cellular Proteomics.

Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in estrogen-negative breast cancers

Lijun Xue, Y. Yen, Xiyong Liu, 2014, BMC Cancer.

Prognostic and therapeutic value of mitochondrial serine hydroxyl-methyltransferase 2 as a breast cancer biomarker

Y. Yen, Xiyong Liu, Hang Zhang, 2016, Oncology reports.

Arginine starvation elicits chromatin leakage and cGAS-STING activation via epigenetic silencing of metabolic and DNA-repair genes

Y. Yen, H. Kung, Cheng-Ying Chu, 2021, Theranostics.

Characterization of Two Novel Cell Lines with Distinct Heterogeneity Derived from a Single Human Bile Duct Carcinoma

Y. Yen, Q. Qian, Mengchao Wu, 2013, PloS one.

Lovastatin overcomes gefitinib resistance through TNF-α signaling in human cholangiocarcinomas with different LKB1 statuses in vitro and in vivo

Y. Yen, Yun-Ru Liu, C. Chen, 2015, Oncotarget.

Paraneoplastic syndromes in cancer: Case 3. Parathyroid hormone-related hypercalcemia in cholangiocarcinoma.

Y. Yen, P. Chu, Wei Feng, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Commentary (Yen/Wagman)—Gallbladder and Biliary Tract Carcinoma: A Comprehensive Update

Y. Yen, L. Wagman, 2004 .

ET-1 Promotes Epithelial–Mesenchymal Transition in Oral Squamous Cell Carcinoma Cells via the microRNA-489-3p /TWIST Axis

Y. Yen, Chun-Hao Tsai, Chih-Hsin Tang, 2021, OncoTargets and therapy.

Chemotherapy for advanced biliary tract carcinoma

Y. Yen, Chiehfeng Chen, K. Tam, 2016, Medicine.

A combination of anti-PD-L1 mAb plus Lm-LLO-E6 vaccine to suppress tumor growth and metastasis in HPV-infected cancers.

Y. Yen, Hue Lee, Po‐Lin Lin, 2017 .

Human papillomavirus infection as a prognostic factor in oropharyngeal squamous cell carcinomas treated in a prospective phase II clinical trial.

Y. Yen, Xiyong Liu, B. Paz, 2009, Anticancer research.

Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer

Y. Yen, J. Sparano, N. Hamel, 2011, Cancer Chemotherapy and Pharmacology.

Wnt modulates MCL1 to control cell survival in triple negative breast cancer

J. Li, Y. Yen, Yun-Ru Chen, 2014, BMC Cancer.

Modern staging and utility of PET imaging in esophageal cancer management.

Y. Yen, Jang-Yang Chang, J. Chao, 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

Inhibition of tumor cell growth by Schiff bases of hydroxysemicarbazide.

Y. Yen, S. Ren, E. Lien, 2001, Anticancer research.

Advances in Brief Overexpression of Ribonucleotide Reductase as a Mechanism of Resistance to 2 , 2-Difluorodeoxycytidine in the Human KB Cancer Cell Line 1

Y. Yen, Bingsen Zhou, S. Mi, 1999 .

Combining an Autophagy Inhibitor, MPT0L145, with Abemaciclib Is a New Therapeutic Strategy in GBM Treatment

Y. Yen, Tsung-Han Hsieh, Yu-chen Lin, 2021, Cancers.

A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer: A Study of the PMH Phase II Consortium

G. Pond, Y. Yen, F. Shepherd, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Inhibition of transketolase by oxythiamine altered dynamics of protein signals in pancreatic cancer cells

Y. Yen, R. Recker, V. Go, 2013, Experimental Hematology & Oncology.

Application of bioconjugation chemistry on biosensor fabrication for detection of TAR-DNA binding protein 43.

Yun Yen, Geneviève Sauvé, C. Liu, 2018, Biosensors & bioelectronics.

Astragalus membranaceus–Derived Anti-Programmed Death-1 Monoclonal Antibodies with Immunomodulatory Therapeutic Effects against Tumors

Y. Yen, K. Tsai, S. Pan, 2020, BioMed research international.

Arginine starvation kills tumor cells through aspartate exhaustion and mitochondrial dysfunction

Dustin E. Schones, Y. Yen, Yun-Ru Chen, 2018, Communications Biology.

The EGF/hnRNP Q1 axis is involved in tumorigenesis via the regulation of cell cycle-related genes

Y. Yen, Chang-Shen Lin, Liang-Yi Hung, 2018, Experimental & Molecular Medicine.

UC Office of the President Recent Work Title Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis

Hanlin Gao, Y. Yen, P. Chu, 2014 .